Korean pharma deal shows value of R&D and brands

Kolmar Korea goes up the value chain with the acquisition of CJ Healthcare to keep one step ahead of potential digital disruption in the sector.

Korean pharma deal shows value of R&D and brands

Drug companies are increasingly deploying artificial intelligence to analyse growing volumes of data for drug development. To acquire this know-how they are making deals, signing partnerships, and designing new product-launch strategies to boost market share.

In that context, Kolmar Korea is buying drugs-to-beauty products group CJ HealthCare for W1.31 trillion $1.2 billion, according to a stock market filing late Tuesday.

A key attraction for Kolmar Korea, which largely makes drugs...

To continue reading, please login or register for free

Click for more on: health | private | equity | korea | kolmar korea | cj healthcare

Print Edition

FinanceAsia Print Edition

EVENTS